Lotus Pharmaceutical Co., Ltd (“Lotus” or “the Company”, 1795:TT) today announced that Alvogen US received a decision from the United States District Court for the District of Delaware that Alvogen’s generics alternative to Indivior’s blockbuster Suboxone film is cleared of infringing US Patent No. 8,603,514, and No. 8,900,497. This is one of the products under strategic alliance between Alvogen US and Lotus and with the decision, the two shall proceed with ANDA related preparations. Meanwhile, the Company is prepared if Indivior appeals.